Who is sponsoring NCT00097383?

NCT00097383 is sponsored by Eli Lilly and Company.

What condition does NCT00097383 study?

NCT00097383 studies Breast Cancer.

What drugs are being tested in NCT00097383?

Interventions: ALIMTA plus Epirubicin.

What is the status of NCT00097383?

NCT00097383 is currently COMPLETED.

Last reviewed 2006-07-18 · How we verify

A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00097383 Phase 1/Phase 2 COMPLETED

This is a non-randomized Phase 2 portion of a study testing ALIMTA and epirubicin in combination for locally advanced or metastatic breast cancer. Epirubicin is a well-established drug for the therapy of breast cancer. Both ALIMTA and epirubicin have been combined with other drugs but they have not yet been combined with each other. It is expected that the patient will benefit from the different mechanisms of action of the two drugs.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 1/Phase 2
Status	COMPLETED

Conditions

Breast Cancer

Interventions

ALIMTA plus Epirubicin

Countries

Argentina, Belgium, Brazil, Mexico, Portugal